Florida Medicaid Finds Sex Reassignment Treatments ‘Experimental’ and ‘Insufficient’ to Show Safety
June 2, 2022 Updated 4:09 P.M. ET
TALLAHASSEE (FLV) – Florida Medicaid released a report Thursday that said research supporting sex reassignment treatment is “insufficient to demonstrate efficacy and safety,” backing up the Florida Department of Health’s recommended guidance against gender transition treatment for minors.
The Secretary of the Agency for Health Care Administration requested Florida Medicaid program review to determine whether certain gender dysphoria treatments including sex reassignment surgery, cross-sex hormones, and puberty blockers are consistent with widely accepted professional medical standards.
The report said there is “weak evidence” supporting the use of puberty suppression, cross-sex hormones, and surgical procedures compared to “stronger research” showing the “permananent effects” they cause.
“These treatments do not conform to GAPMS (Generally Accepted Professional Medical Standards) and are experimental and investigational,” the report said.
The report listed the irreversible from cross-sex hormones including body hair growth, male-pattern baldness, enlarged clitoris, deepening voice for female to male transitions, breast growth, and infertility for male to female transitions.
Ladapo: “Fear” To Speak Against Gender-Affirming Care is Not Part of Scientific Method
The Florida Department of Health published a fact sheet to deter families from giving their children gender-affirming care to treat gender dysphoria. The fact sheet was in response to the Biden Administration encouraging gender-affirming care for young people.
Florida’s fact sheet said social gender transition should not be an option for children and anyone under 18 should not be prescribed puberty blockers or hormone therapy. The sheet also said gender reassignment surgery should not be a treatment option for children or adolescents.
